Melanoma High-Impact Publications | NYU Langone Health

Skip to Main Content
Melanoma Research Program Melanoma High-Impact Publications

Melanoma High-Impact Publications

Investigators in the Melanoma Research Program at Perlmutter Cancer Center publish high-impact studies about melanoma treatments and other advances.

Weber JS … Roder H. A serum protein signature associated with outcome after anti-PD-1 therapy in metastatic melanoma. Cancer Immunol Res. 2018. DOI.

Agrawal P … Hernando E. A systems biology approach identifies FUT8 as a driver of melanoma metastasis. Cancer Cell. 2017. DOI.

Bordia R … Jain R. Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival. J Neurooncol. 2017. DOI.

Fontanals-Cirera B … Bernstein E. Harnessing BET inhibitor sensitivity reveals AMIGO2 as a melanoma survival gene. Mol Cell. 2017. DOI.

Long GV … Wolchok JD. Nivolumab for patients with advanced melanoma treated beyond progression: Analysis of 2 phase 3 clinical trials. JAMA Oncol. 2017. DOI.

Terushkin V … Polsky D. A prospective study evaluating the utility of a 2-mm biopsy margin for complete removal of histologically atypical (dysplastic) nevi. J Am Acad Dermtol. 2017. DOI.

Vitiello M … Poliseno L. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 2017. DOI.

Weber J … Ascierto PA. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017. DOI.

Weber JS … Robert C. Safety profile of Nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017. DOI.

Moogk D … Krogsgaard M. Constitutive Lck activity drives sensitivity differences between CD8+ memory T cell subsets. J Immunol. 2016. DOI.

Vogelsang M … Kirchhoff T. The expression quantitative trait loci in immune pathways and their effect on cutaneous melanoma prognosis. Clin Cancer Res. 2016. DOI.

Weber J … Chen YA. Phase I/II study of metastatic melanoma patients treated with Nivolumab who had progressed after Ipilimumab. Cancer Immunol Res. 2016. DOI.